Treatment of hepatitis B with interferon and combination therapy

Clinics in Liver Disease

Volumn 8, Issue 2, 2004, Pages 353-370

  Cooksley, W Graham ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; CORTICOSTEROID; ENTECAVIR; HEPATITIS B(E) ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INTERFERON; LAMIVUDINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2A INTERFERON; STEROID;

ACUTE DISEASE; CHRONIC DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DNA HYBRIDIZATION; DRUG EFFECT; DRUG HALF LIFE; DRUG RESPONSE; DRUG SCREENING; DRUG UTILIZATION; FEVER; FLU LIKE SYNDROME; GENETIC ANALYSIS; GENOTYPE; HEPATITIS B; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; MONOTHERAPY; MORTALITY; MYALGIA; NEUTROPENIA; OUTCOMES RESEARCH; PATIENT; PATIENT CARE; PATIENT MONITORING; REVIEW; SEROCONVERSION; SIDE EFFECT; STATISTICAL ANALYSIS; SURVIVAL; THROMBOCYTOPENIA; TREATMENT INDICATION; VIRAL GENETICS; VIRUS LOAD;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS B CORE ANTIGENS; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LAMIVUDINE; POLYETHYLENE GLYCOLS; RECURRENCE;

EID: 2942558750     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2004.02.004     Document Type: Review

References (73)

1. Greenberg H.B., Pollard R.B., Lutwick L.I., Gregory P.B., Robinson W.S., Merigan T.C. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med. 295:1976;517-522
2. Lok A.S., Heathcote E.J., Hoofnagle J.H. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology. 120:2001;1828-1853
3. The EASL Jury EASL International Consensus Conference on Hepatitis B, 13-14 September, 2002, Geneva, Switzerland. Consensus statement (short version). J Hepatol. 38:2003;533-540
4. Almasio P., Camma C., Giunta M., Craxi A. Treatment of chronic hepatitis B: an evidence-based review. McDonald J.W.D., Burroughs A., Feagan B.G. Evidenced-based gastroenterology and hepatology. 1999;305-321 BMJ publ, London
5. Wong J., Koff R.S., Tiné F., Paukder S.G. Cost-effectiveness of interferon alpha-2b treatment for hepatitis Be antigen-positive chronic hepatitis B. Ann Intern Med. 122:1995;664-675
6. Tiné F., Liberati A., Craxi A., Almasio P., Pagliaro L. Interferon treatment in patients with chronic hepatitis B: a meta-analysis of the published literature. J Hepatol. 18:1993;154-162
7. Wong D.K., Cheung A.M., O'Rourke K., Naylor C.D., Detsky A.S., Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. a meta-analysis. Ann Intern Med. 119:1993;312-323
8. Craxi A., Di Bona D., Camma C. Interferon alpha for HBeAg positive chronic hepatitis B: systemic review. J Hepatol. 39(Suppl 1):2003;S99-S105
9. Alexander G.J., Brahm J., Fagan E.A., Smith H.M., Daniels H.M., Eddleston A.L., et al. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection. Lancet. 8550:1987;66-69
10. Carreno V., Porres J.C., Mora I., Gutiez J., Quiroga J.A., Ramon Y., et al. A controlled study of treatment with recombinant interferon alpha in chronic hepatitis B virus infection: induction and maintenance schedules. Antiviral Res. 3:1987;127-137
11. McDonald J.A., Caruso L., Karayiannis P., Scully L.J., Harris J.R., Forster G.E., et al. Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-111 antibodies to recombinant alpha-interferon. Hepatology. 7(4):1987;719-723
12. Hoofnagle J.H., Peters M., Mullen K.D., Jones D.B., Rustgi V., Di Bisceglie A., et al. Randomized controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology. 95:1998;1318-1325
13. Lok A.S., Lai C.L., Wu P.C., Leung E.K. Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet. 2:1998;298-302
14. Porres J.C., Carreno V., Mora I., Gutiez J., Moreno A., Cajal S.R., et al. Different doses of recombinant alpha interferon in the treatment of chronic hepatitis B patients without antibodies against the human immunodeficiency virus. Hepatogastroenterology. 6:1988;300-303
15. Pastore G., Santantonio T., Monno L., Milella M., Luchena N., Angarano G. Permanent inhibition of viral replication induced by low dosage of human leukocyte interferon in patients with chronic hepatitis B. Hepatogastroenterology. 35-2:1988;57-61
16. Brook M.G., McDonald J.A., Karayiannis P., Caruso L., Forster G., Harris J.R., et al. Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response. Gut. 30:1989;1116-1122
17. Brook M.G., Chan G., Yap I., Karayannis P., Lever A.M.L., Jacyna M., et al. Randomised controlled trial of lymphoblastoid IFN alfa in Europid men with chronic hepatitis B virus infection. BMJ. 299:1989;652-656
18. Saracco G., Mazzella G., Rosina F., Cancellieri C., Lattore V., Raise E., et al. A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy. Hepatology. 10:1989;336-341
19. Fattovich G., Brollo L., Boscaro S., Pontisso P., Giustina G., Criscuolo D., et al. Long-term effect of low dose recombinant interferon therapy in patients with chronic hepatitis B. J Hepatol. 3:1989;331-337
20. Muller R., Baumgarten R., Markus R., Schutz M., Wittenberg H., Hintsche-Kilger B., et al. Treatment of chronic hepatitis B with interferon alfa-2b. J Hepatol. 11(Suppl 1):1990;S137-S140
21. Perrillo R.P., Schiff E.R., Davis G.L., Bodenheimer H.C. Jr., Lindsay K., Payne J., et al. A randomized, controlled trial of interferon alfa-2b alone after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med. 19:1990;295-301
22. Williams S.J., Craig P.I., Cooksley W.G., Bye W.A., Bilous M., Grierson J.M., et al. Randomised controlled trial of recombinant human interferon-alpha A for chronic hepatitis B. Aust NZ J Med. 20:1990;9-19
23. Waked I., Amin M., Abd el Fattah S., Osman L.M., Sabhour M.S. Experience with interferon in chronic hepatitis B in Egypt. J Chemother. 2:1990;310-318
24. Realdi G., Fattovich G., Pastore G., Caredda F., Noventa F., Santantonio T., et al. Problems in the management of chronic hepatitis B with interferon: experience in a randomized multicentre study. J Hepatol. 11(Suppl 1):1990;S129-S132
25. Lok A.S., Wu P.C., Lai C.L., Lau J.Y., Leung E.K., Wong L.S., et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology. 102(6):1992;2091-2097
26. Di Bisceglie A.M., Fong T.L., Fried M.W., Swain M.G., Baker B., Korenman J., et al. A randomized controlled trial of recombinant alpha-interferon therapy for chronic hepatitis. Am J Gastroenterol. 88:1993;1887-1892
27. Bayraktar Y., Uzunalimoglu B., Arslan S., Koseoglu T., Kayhan B., Telatar H. Effects of recombinant interferon on chronic active hepatitis B: preliminary results. Gut. 34(2 Suppl):1993;S101
28. Muller R., Baumgarten R., Markus R., Schulz M., Wittenberg H., Hintsche-Kilger B., et al. Low dose alpha interferon treatment in chronic hepatitis B virus infection. Gut. 34(Suppl):1993;S97-S98
29. Wong D.K., Yim C., Naylor C.D., Chen E., Sherman M., Vas S., et al. Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly homosexual population. Gastroenterology. 108:1995;165-171
30. Sarin S.K., Guptan R.C., Thakur V., Malhotra S., Malhotra V., Banerjee K., et al. Efficacy of low-dose alpha interferon therapy in HBV-related chronic liver disease in Asian Indians: a randomized controlled trial. Hepatology. 24:1996;391-396
31. Janssen H.L., Gerken G., Carreno V., Marcellin P., Naoumov N.V., Craxi A., et al. Interferon alpha for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology. 30:1999;238-243
32. Thomas H.C., Lok A.S.F., Carreno V., et al. Comparative study of three doses of interferon alfa-2a in chronic active hepatitis B. J Viral Hepat. 1:1994;139-148
33. Niederau C., Heintges T., Lange S., Goldmarm G., Niederau C.M., Mohr L., et al. Long-term follow-up HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 334:1996;1422-1427
34. Lin S.M., Sheen I.S., Chien R.N., Chu C.M., Liaw Y.F. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 29:1999;971-975
35. Fattovich G., Giustina G., Realdi G., Corrocher R., Schalm S.W. Long-term outcome of hepatitis B e antigen positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology. 26:1997;1338-1342
36. Di Marco V., Lo Iacono O., Camma C., Vaccaro A., Giunta M., Martorana G., et al. The long-term course of chronic hepatitis B. Hepatology. 30:1999;257-264
37. Yuen M.F., Hui C.K., Cheng C.C., Wu C.H., Lai Y.P., Lai C.L. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection. The effect on hepatitis B e antigen seroconversion and development of cirrhosis-related complications. Hepatology. 34:2001;139-145
38. Chen D.K., Yim C., O'Rourke K., Krajden M., Wong D.K., Heathcote E.J. Long-term follow-up of a randomised trial of interferon therapy for chronic hepatitis B in a predominantly homosexual male population. J Hepatology. 30:1999;557-563
39. Evans A., Fine M., London W.T. Spontaneous seroconversion in hepatitis B e antigen-positive chronic hepatitis B: implications for interferon therapy. J Infect Dis. 176:1997;845-850
40. Korenman J., Baker B., Waggoner J., Everhart J.E., Di Bisceglie A.M., Hoofnagle J.H. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med. 114:1991;629-634
41. Lok A.S., Chung H.T., Liu V.W., Ma O.C. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology. 105:1993;1833-1838
42. Lau D.T., Everhart J., Kleiner D.E., Park Y., Vergalla J., Schmid P., et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology. 113:1997;1660-1667
43. Fattovich G., Giustina G., Christensen E., Pantalena M., Zagni I., Readldi G., et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut. 46:2000;420-426
44. Hsu U.S., Chien R.N., Yeh C.T., Sheen I.S., Chiou H.Y., Chu C.M., et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 35:2002;1522-1527
45. Brunetto M.R., Oliveri F., Coco B., Leandro G., Colombatto P., Monti Gorin J., et al. The outcome of chronic anti-HBe positive chronic hepatitis B in alpha interferon treated and untreated patients: a long term cohort study. J Hepatol. 36:2002;263-270
46. Brunetto M.R., Oliveri F., Colombatto P., Coco B., Ciccorossi P., Bonino F. Treatment of HBeAg negative chronic hepatitis B. J Hepatology. 39(Suppl 1):2003;S164-S167
47. Hadziyannis S., Bramou T., Makris A., Moussoulis G., Zignego L., Papaioannou C. Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis B. J Hepatol. 11:1990;S133-S136
48. Pastore G., Santantonio T., Milella A., Monno L., Mariano N., Moschetta R., et al. Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum: response to a 6-month course of lymphoblastoid interferon. J Hepatol. 20:1992;221-225
49. Fattovich G., Farci P., Rugge M., Brollo L., Mandas A., Pontisso P., et al. A randomized controlled trial of lymphoblastoid interferon-alfa in patients with chronic hepatitis B lacking HBeAg. Hepatology. 26:1992;1621-1625
50. Lampertico P., Del Ninno E., Manzin A., Donato M.F., Rumi M.G., Lunghi G., et al. A randomized controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology. 26:1997;1621-1625
51. Manesis E.K., Hadziyarnis J. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology. 121:2001;101-109
52. Papatheodoridis G.V., Manesis E., Hadziyannis S.J. The long term outcome of interon-alpha treated and untreated patients with HBeAg -negative chronic hepatitis B. J Hepatol. 34:2001;306-313
53. Lampertico P., Del Ninno E, Vigano M., Romeo R., Donato M.F., Sablon E., et al. Extended interferon therapy increases hepatitis suppression and reduces liver-related morbidity of hepatitis B e antigen negative chronic active hepatitis B. Gastroenterology, in press
54. Mutimer D., Naoumov N., Honkoop P., Marinos G., Ahmed M., de Man R., et al. Combination alpha-interferon and lamivudine therapy for alpha interferon-resistant chronic hepatitis B infection: results of a pilot study. J Hepatol. 28:1998;923-929
55. Schiff E.R., Karayalcin S., Grimm I., Perillo R., Dienstag J., Husa P., et al. A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy [abstract]. Hepatology. 28:1998;388A
56. Schalm S.W., Heathcote H., Cianciara J., Farrell G., Sherman M., Willems B., et al. Lamivudine and alpha combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut. 46:2000;562-568
57. Barbaro G., Zechini F., Pellicefli A.M., Francavilla R., Scotto G., Bacca D., et al. Long-term efficacy of alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with hepatitis B: an Italian multicenter randomized trial. J Hepatol. 35:2001;406-411
58. Sanantonio T., Niro G.A., Sinisi E., Leandro G., Insalata M., Pastore G., et al. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B: a controlled pilot study. J Hepatol. 36:2002;799-804
59. Perry C.M., Jarvis B. Spotlight on peginterferon-alpha-2a (40kDa) in chronic hepatitis C. BioDrugs. 16:2002;213-217
60. Glue P., Fang J.W.S., Pouzier-Panis R., et al. Pegylated interferon alpha-2b, pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther. 69:2000;556-557
61. Formann E., Jessner W., Bennett L., Ferenci P. Twice-weekly administration of peginterferon-α-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. J Viral Hepat. 10:2003;271-276
62. Cooksley W.G.E., Piratvisuth R., Lee S.-D., Mahachai V., Chao Y.-C., Tanwandee T., et al. Peginterferon α-2a (40kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat. 10(4):2003;298-305
63. Cooksley W.G.E., Lai M.-Y., Piratvisuth T., Mahachai V., Chao Y.-C., Tanwandee T., et al. Treatment with peginterferon alfa-2a (40kDa) (PEGASYS) results in improved rates of response compared to conventional interferon in patients with HBeAg positive chronic hepatitis B harboring HBV genotypes B and 'difficult-to-treat' genotype C. J Hepatol. 38S2:2003;25
64. Kao J.H. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol. 17:2002;643-650
65. Sung J.J.Y., Chan H.L.Y., Hui A.Y., Chan F.K.L., Chim A.M.L., Wong M.L., et al. Combination of pegylated interferon and lamivudine is superior to lamivudine monotherapy in the treatment of chronic hepatitis B - a randomized trial. J Hepatol. 38S2:2003;33
66. Schramm T.M., Lawford B.R., Macdonald G., Cooksley W.G.E. Case reports on highly effective sertraline treatment of interferon-a induced depressive disorder. Med J Aust. 173:2000;359-361
67. Scheuer P.J. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 13:1991;372-374
68. Hadziyannis F., Tassopoulos N., Heathcote J., Chang T.T., Kitis G., Rizetto M., et al. Two year results from a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B. J Hepatol. 38(S2):2003;143
69. Liaw Y.-F., Sung J.J.Y., Chow W.C., Shue K. Lamivudine delays clinical progression and reduces incidence of liver cancer in patients with HBV related cirrhosis - results of a prospective placebo-controlled clinical trial. J Gastroenterol Hepatol, in press
70. Tassopoulos N.C., Volpes R., Pastore G., Heathcote J., Buti M., Goldin R.D., et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology. 29:1999;889-896
71. Lau D.T.-Y., Khokhar M.F., Doo E., Ghany M.G., Herion D., Park Y., et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology. 32:2000;828-834
72. McIvor C., Bryant A., Morton J., Cooksley W.G.E., Durrant S., Walker N. Fatal reactivation of precore mutant hepatitis B virus with fibrosing cholestatic hepatitis after bone marrow transplantation. Ann Intern Med. 121:1994;274-275
73. Cooksley W.G.E., McIvor C. Fibrosing cholestatic hepatitis and HBV after bone marrow transplantation. Biomed Pharmacol. 49:1995;117-124